Millennium Management’s Checkpoint Therapeutics CKPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-401,816
Closed -$1.62M 5907
2025
Q1
$1.62M Buy
401,816
+347,630
+642% +$1.16M ﹤0.01% 3980
2024
Q4
$173K Buy
+54,186
New +$184K ﹤0.01% 5348
2024
Q3
Sell
-39,212
Closed -$84.3K 6134
2024
Q2
$84.3K Sell
39,212
-24,221
-38% -$43.1K ﹤0.01% 5340
2024
Q1
$130K Buy
63,433
+51,512
+432% +$103K ﹤0.01% 5513
2023
Q4
$27.3K Sell
11,921
-9,418
-44% -$20.5K ﹤0.01% 5590
2023
Q3
$36.3K Buy
+21,339
New +$48.5K ﹤0.01% 5543
2023
Q1
Sell
-36,878
Closed -$188K 6424
2022
Q4
$188K Sell
36,878
-18,301
-33% -$132K ﹤0.01% 5355
2022
Q3
$574K Sell
55,179
-28,759
-34% -$343K ﹤0.01% 4841
2022
Q2
$865K Sell
83,938
-29,445
-26% -$386K ﹤0.01% 4507
2022
Q1
$2.01M Buy
113,383
+32,578
+40% +$700K ﹤0.01% 3877
2021
Q4
$2.51M Sell
80,805
-3,013
-4% -$99.8K ﹤0.01% 3556
2021
Q3
$2.77M Sell
83,818
-18,725
-18% -$553K ﹤0.01% 3537
2021
Q2
$3.02M Buy
102,543
+89,983
+716% +$2.49M ﹤0.01% 3426
2021
Q1
$394K Sell
12,560
-25,709
-67% -$862K ﹤0.01% 5014
2020
Q4
$1.01M Buy
38,269
+27,379
+251% +$693K ﹤0.01% 3730
2020
Q3
$292 Buy
10,890
+1,278
+13% +$30.7K ﹤0.01% 3858
2020
Q2
$190K Buy
9,612
+5,208
+118% +$94.9K ﹤0.01% 3858
2020
Q1
$67K Sell
4,404
-4,025
-48% -$71.2K ﹤0.01% 3624
2019
Q4
$145K Buy
+8,429
New +$141K ﹤0.01% 3945
2019
Q3
Sell
-4,091
Closed -$124K 4211
2019
Q2
$124K Buy
+4,091
New +$161K ﹤0.01% 3860
2018
Q2
Sell
-7,539
Closed -$331K 3818
2018
Q1
$331K Buy
+7,539
New +$327K ﹤0.01% 3176

Millennium Management's CKPT Position: Q2 2025 in Review

Millennium Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 401,816 shares — an estimated $1.62M sold.

Millennium Management first reported a position in CKPT in Q1 2018 and held it in 21 quarters. The position peaked at $3.02M in Q2 2021. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.

  • Millennium Management reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Millennium Management sold 401,816 Checkpoint Therapeutics shares in Q2 2025, an estimated $1.62M.
  • Millennium Management first reported a position in Checkpoint Therapeutics in Q1 2018 and held it in 21 quarters.
  • Millennium Management's Checkpoint Therapeutics position peaked at $3.02M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.

Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.